Skip to main content
Biohaven Ltd. logo

Biohaven Ltd. — Investor Relations & Filings

Ticker · BHVN ISIN · VGG111961055 LEI · 5299007STZTNN32O9920 US Manufacturing
Filings indexed 240 across all filing types
Latest filing 2024-01-05 Director's Dealing
Country VG Virgin Islands (British)
Listing US BHVN

About Biohaven Ltd.

https://www.biohaven.com/

Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas of focus are neuroscience, immunology, and oncology. Biohaven is advancing a portfolio of late- and early-stage drug development programs, building upon its legacy of success in transforming migraine treatment with Nurtec® ODT (rimegepant) and Zavzpret® (zavegepant). The company utilizes proprietary drug development platforms and combines internal research with intellectual property licensed from global institutions to address a broad range of rare and common diseases.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2023-12-30 English
Regulatory Filings 2023
Regulatory Filings
2023-12-29 English
8-K
Regulatory Filings
2023-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.